Brooklyn Roasting Company recalls cold brew sold in New York and New Jersey over botulism risk

Brooklyn Roasting Company has initiated a food safety recall of its cold brew concentrate product. The recall is specifically targeting items distributed and sold within the states of New York and New Jersey. According to the reports, the volume of the product being recalled totals 3,000 gallons. The primary driver for this action is the risk of botulism, a serious health concern associated with certain contaminated food products. This effort to remove the concentrate from consumer reach is being executed across these two specific regional markets to prevent potential illness. Multiple media outlets have reported on the situation, including Fox Business, which highlighted the company's recall efforts in both New York and New Jersey.

PIX11 cited the FDA as the source regarding the botulism risk associated with the coffee. Yahoo provided the specific scale of the recall, noting that 3,000 gallons of the beverage are affected. Additional coverage was provided by the Brooklyn Eagle, focusing on the food safety aspect of the cold brew concentrate, and The Healthy via Reader's Digest, which emphasized that the recall spans two states. To understand the significance of this event, it is necessary to note the nature of the product involved: a cold brew concentrate. The risk identified is botulism, a condition that necessitates urgent public health intervention and the removal of contaminated goods from the supply chain. The concentration of the recall in the New York and New Jersey areas indicates the geographic distribution of the affected batches.

The involvement of the FDA indicates that the recall is being monitored or directed by federal regulatory standards to ensure consumer safety. Moving forward, the situation will likely involve the continued monitoring of the 3,000 gallons of recalled product to ensure they are successfully removed from shelves. Consumers in New York and New Jersey who purchased the Brooklyn Roasting Company cold brew concentrate are the primary group affected. Further updates will likely depend on the findings of the FDA and the company's ability to secure the remaining product. Coverage does not yet specify the exact batch numbers or specific retail locations where the cold brew was sold.